Northumbria University, one of the UK's largest universities, may improve the treatment of diseases caused by genetic mutations, such as cancer, cystic fibrosis and other 6,000 other underlying genetic diseases.
It is understood that scientists have invented a technique for predicting how patients respond to the treatment of directly targeted mutant genes by using viral genomics (genetic material), big data analysis, and gene coding, even without touching patients. Currently, this technology can be directly applied to DNA drugs on the market, 32 clinical drug candidates, and future treatment methods such as genome editing.
Researchers have achieved this by using cultures of human liver cancer cells containing non-infectious hepatitis C virus and by treating and damaging their genomes to treat hepatitis C drugs. Hepatitis C virus is not good at replicating its genome, producing tens of billions of variants in cells, similar to genetic mutations that can be found in a wider population.
Therefore, the researchers tested the drugs for the treatment of hepatitis C virus and studied the effects of each drug on each variant of the hepatitis C virus to determine which drugs worked for which variants and to what extent. kick in. Although current drugs for treating hepatitis C are generally effective, they are expensive and do not work for all patients. The finding may allow for more targeted and personalized treatment for patients who use these drugs, allowing them to safely take medication and increase confidence in the effectiveness of the drug.
In addition, the technology will have a major impact on drug development, as companies and physicians can know in advance which patient clinical trials can be selected, making clinical trials more likely to succeed and speeding up the development of new drugs. Similarly, after the new drug is approved, the doctor will be able to perform a simple check and prescribe safely and with confidence.
Dr. Sterghios A. Moschos, an associate professor at the School of Cell and Molecular Sciences at Northumbria University who led the study, said: "There is no way to know which drugs are effective for patients. This is a real breakthrough, making these types of gene therapy even more Quickly approach patients, making them safer and more effective at the same time. This is not only expensive and dangerous for pharmaceutical companies and institutions that pay for drugs, it is also a therapeutic risk for patients themselves. A long process.
The researchers say their next step is to plan how to use the technology as a single predictive test for clinical research and clinical applications, enabling us to predict which patients may respond to certain types of gene therapy, and their doses. What is it, whether it is experimental or approved.
"This approach will also play an important role in a new type of gene therapy called gene editing. Clinical trials of genetic editing are about to begin in the United States, removing diseased genes from patients and replacing them with healthy genes." Dr. Sterghios A. Moschos said.
Shanghai Chuangsai Technology has excellent performance, interleukin cytokines, fetal bovine serum, electrophoresis equipment scientific instruments, raw material drug standards, chemical reagents, cell culture consumables, Shanghai Chuangsai, mass products special promotions, welcome to inquire!
Fixed Single Desk And Chair,School Table Desk,Study Chair Set,Classroom Desk And Chair
AU-PINY FURNITURE CO., LTD , https://www.jmaupiny.com